Рандомизированное исследование трех методов инфузии декстрана железа при анемии у диализных пациентов, получающих терапию эритропоэтином
Аннотация
Об авторах
М. . АуэрбахРоссия
Д. . Винчестер
Россия
А. . Вахаб
Россия
К. . Ричардс
Россия
М. . Макгинли
Россия
Ф. . Холл
Россия
Д. . Андерсон
Россия
Г. . Брифель
Россия
Список литературы
1. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134-148, 1989.
2. McDougall IC, Hutton RD, Cavill I, Coles GA, Williams JD: Poor response to treatment of renal anemia with erythropoietin corrected by iron given intravenously. Br Med J 299: 157-158, 1989.
3. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz M, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35: 712-716, 1989.
4. Jacobs P,Wood L: Clinical use of total dose infusion of iron dextran. S Afr Med J 67: 837-838, 1985.
5. Hanson DB, Hendeles L: Guide to total dose intravenous iron dextran.Am J Hosp Pharm 31: 592-595, 1974.
6. Auerbach M, Witt D, TolerW, Fierstein M, Lerner RG, Ballard H: Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 111: 566-570, 1988.
7. Donnelly SM, Posen GA, Mahmoud AMA: Iron metabolism in patients with chronic renal failure. Clin Invest Med 14: 271-276, 1991.
8. Hughes RT, Smith T, Hesp R, Hulme B, Dukes DC, Bending MB, Pearson J, Raja KB, Cotes PM, Pippard MJ: Regulation of iron absorption in iron loaded subjects with end stage renal disease: Effects of treatment with recombinant human erythropoietin and reduction in iron stores. Br J Haematol 82: 445-454, 1992.
9. El-Reshaid K, Johny KV, Hakim A, Kamel A, Sabeta A, Hourani H, Kanyike FB: Erythropoietin treatment in haemodialysis patients with iron overload. Acta Haematol 91: 130-135, 1994.
10. Grutzmacher P, Tsobanelis T, Roth P, Werner E, Vlachojannis J, Kaltwasser J, Kurz P, Scheuremann EH, Schoeppe W: Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: Theoretical considerations, clinical experience and consequences. Clin Nephrol 38: 92-97, 1992 (suppl 1).
11. Watson A: Iron management during treatment with recombinant human erythropoietin in chronic renal failure. J Clin Pharmacol 33: 1134-1138, 1992.
12. Goldwasser P, Koutelos T, Abraham S, Avram MM: Serum ferritin, hematocrit and mean corpuscular volume in hemodialysis. Nephron 67: 30-35, 1994.
13. Eschbach JW, Haley NR, Egrie JC, Adamson JW: A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 42: 407-416, 1992.
14. Kooistra MP, van Es A, Struyvenberg A, Marx JJ: Iron metabolism in patients with the anaemia of end stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79: 634-639, 1991.
15. Barosi G, Merlo C, Palestra P, Liberato NL, Guarnone R, DiDio F, Piazza V, Salvadeo A: Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end stage renal disease. Acta Haematol 90: 13-18, 1993.
16. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V,Wish J: The safety of intra-venous iron dextran in hemodialysis patients. Kidney Int 28:529-534, 1966.
17. Henderson PA, Hillman RS: Characteristics of iron dextran utilization in man. Bolld 34: 357-375, 1969.
18. Vercammen M, Goedhuys W, Boeyckens A, DeRoy R: Iron and total iron binding capacity in serum of patients receiving iron-dextran Kodak Ektachem methodologies, spectrophotometry, and atomic absorption spectrophotometry compared. Clin Chem 36: 1812-1815, 1990.
19. Greenberg G: Sarcoma after intramuscular iron injection. Br Med J 2: 227-279, 1973.
20. Foulkes WD, Sewry C, Calam J, Hodgson HJ: Rhabdomyolysis after intramuscular iron-dextran in malabsorption. Ann Rheum Dis 50: 184-186, 1991.
21. Bregman H, Gelfand MC, Winchester JF, Manz HJ, Knepshield JH, Schreiner GE: Iron overload associated myopathy in patients on maintenance hemodialysis: A histocompatibility linked disorder. Lancet 2: 882-885, 1980.
22. Kothari T, Swamy AP, Lee JCK, Mangla JC, Cestero RVM: Hepatic hemosiderosis in maintenance hemodialysis patients. Dig Dis Sci 25: 363-368, 1980.
23. Salahudeen AK, Keavey PM, Hawkins T, Wilkinson R: Is anaemia during continuous ambulatory peritoneal dialysis really better than during haemodialysis. Lancet 2: 1046-1049, 1983.
24. Akmal M, Sawelson S, Karubian F, Gadallah M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic treatment. Clin Nephrol 42: 198-202, 1994.
25. Sloand JA, Schiff MJ, Tailey TE: Safety, efficacy and administrative time (AT) comparison between total dose (TD) and multiple dose (MD) Imferon in CRF patients. Blood 78: 388, 1991 (suppl).
26. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41-46, 1995.
27. Shuttleworth D, Spence G, Slade R: Meningismus due to intravenous iron dextran. Lancet 2: 4523, 1985.
28. Roe DJ, Harford AM, Zager PG,Wiltbank TB, Kirlin L, Della Valle AM, VanWyck DB: Iron utilization with iron dextran administration for iron deficiency in patients with dialysis-associated anemia: Aprospective analysis and comparison of two agents.Am J Kidney Dis 28: 855-860, 1996.
29. St. Peter WL, Lambrecht LJ, Macres M: Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28: 523-528, 1996.
30. Kanakaraddi VP, Hoskatti CG, Nadig VS, Patil CK, Jaiya M: Comparative therapeutic study of TDI and IM injections of iron dextran in anemia. J Assoc Phys India 21: 849-853, 1973.
Рецензия
Для цитирования:
Ауэрбах М., Винчестер Д., Вахаб А., Ричардс К., Макгинли М., Холл Ф., Андерсон Д., Брифель Г. Рандомизированное исследование трех методов инфузии декстрана железа при анемии у диализных пациентов, получающих терапию эритропоэтином. Нефрология и диализ. 2007;9(3):247-252.
For citation:
Auerbach M., Winchester J., Wahab A., Richards K., Mcginley M., Hall F., Anderson J., Briefel G. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Nephrology and Dialysis. 2007;9(3):247-252. (In Russ.)